Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen
Accession Number
DB10990
Description

Haemophilus influenzae type b strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen is an active immunization as a booster dose given intramuscularly to pediatric patients who have received a primary series with a Haemophilus b Conjugate Vaccine that is licensed for primarly immunization. The vaccine contains Haemophilus b capsular polysaccharide (polyribosyl-ribitol-phosphate [PRP]), which is a high molecular weight polymer prepared from the Haemophilus influenzae type b strain 20,752. These are heat inactivated and purified.

Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Vaccines
Toxoid
Synonyms
  • Haemophilus influenzae type b strain 20752, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine

Pharmacology

Indication

Indicated for active immunization in pediatric patients 15 months through 4 years of age as a booster dose for the prevention of invasive disease caused by Haemophilus influenzae type b.

Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbataceptThe therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Abatacept.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen is combined with Acetylsalicylic acid.
AdalimumabThe therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Adalimumab.
AldesleukinThe therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Aldesleukin.
AlefaceptThe therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Alefacept.
AlemtuzumabThe therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Alemtuzumab.
AltretamineThe therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Altretamine.
Aminosalicylic acidThe risk or severity of adverse effects can be increased when Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen is combined with Aminosalicylic acid.
AmsacrineThe therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Amsacrine.
AnakinraThe therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Anakinra.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
HiberixInjection, powder, lyophilized, for solution10 ug/0.5mLIntramuscularGlaxoSmithKline Biologicals SA2009-08-242009-08-19Us
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
HiberixHaemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen (10 ug/0.5mL) + Water (1 mL/1mL)KitIntramuscularGlaxoSmithKline Biologicals SA2015-12-21Not applicableUs

Categories

Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
C9R35M8XV6
CAS number
Not Available

References

General References
Not Available
PubChem Substance
347911072
RxNav
1300806

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Active Not RecruitingPreventionInfections, Pneumococcal1
3Active Not RecruitingPreventionInfections, Pneumococcal / Vaccines, Pneumococcal1
3CompletedPreventionAcellular Pertussis / Diphtheria / Haemophilus Influenzae Type b Diseases / Pertussis / Tetanus2
3CompletedPreventionAcellular Pertussis / Diphtheria / Haemophilus Influenzae Type b Diseases / Poliomyelitis / Poliovirus / Tetanus / Viral Hepatitis B / Whooping Cough1
3CompletedPreventionAcellular Pertussis / Diphtheria / Haemophilus Influenzae Type B / Haemophilus Influenzae Type b Diseases / Pertussis / Poliomyelitis / Tetanus1
3CompletedPreventionAcellular Pertussis / Diphtheria / Haemophilus Influenzae Type B / Poliomyelitis / Tetanus / Viral Hepatitis B1
3CompletedPreventionDiphtheria / Diphtheria-Tetanus-Pertussis-Hepatitis B-Haemophilus Influenzae Type b-Neisseria Meningitidis Vaccin / Haemophilus Infections / Haemophilus Influenzae Type B / Meningococcal Infections / Pertussis / Tetanus / Viral Hepatitis B / Whole Cell Pertussis2
3CompletedPreventionDiphtheria / Haemophilus Infections / Meningococcal Infections / Pertussis / Tetanus / Viral Hepatitis B1
3CompletedPreventionDiphtheria / Haemophilus Influenzae Type b (Hib) / Pertussis / Poliomyelitis / Tetanus / Viral Hepatitis B1
3CompletedPreventionDiphtheria / Haemophilus Influenzae Type B / Haemophilus Influenzae Type b Diseases / Pertussis / Tetanus / Viral Hepatitis B / Whole Cell Pertussis2

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, powder, lyophilized, for solutionIntramuscular10 ug/0.5mL
KitIntramuscular
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on December 01, 2015 13:04 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates